Dale A. Sander

This profile gathers the share dealings of Dale A. Sander in Humacyte, Inc., where the filings describe the role as finance chief. We count 7 filings; the first trade dates from 17 May 2022 and the latest from 16 November 2025.

On the open market, the record shows 3 purchases worth €85k and 1 sale worth €235k. Taken together, the sales exceed the purchases by €151k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 1 share grant and 1 option exercise. Since January 2025: 1 purchase and no sales on the market.

The median purchase comes to €27k. Of 3 purchases, 2 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

Most recently, on 17 November 2025, the filings show a share grant in Humacyte, Inc. The last purchase on record was published on 14 April 2025, which is 558 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.